MORGAN STANLEY PLC/CALL/MADRIGAL PHARMACEUTICALS/300/0.02/20.09.24 Stock MORGAN STANLEY PLC/CALL/MADRIGAL PHARMACEUTICALS/300/0.02/20.09.24
Add to a list
To use this feature you must be a member
Log inSign up

MORGAN STANLEY PLC/CALL/MADRIGAL PHARMACEUTICALS/300/0.02/20.09.24 Stock

Warrant

DE000ME9H262

Delayed Börse Stuttgart 11:32:46 2024-07-16 EDT
0.43 EUR +4.88% Intraday chart for MORGAN STANLEY PLC/CALL/MADRIGAL PHARMACEUTICALS/300/0.02/20.09.24
Current month-12.77%
1 month-16.33%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart MADRIGAL PHARMACEUTICALS, INC.
Chart MORGAN STANLEY PLC/CALL/MADRIGAL PHARMACEUTICALS/300/0.02/20.09.24

Latest news about MADRIGAL PHARMACEUTICALS, INC.

JMP Securities Raises Price Target on Madrigal Pharmaceuticals to $385 From $381, Maintains Market Outperform Rating MT
Non Alcoholic Fatty Liver Disease Pipeline 2024 | Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceutical AQ
Cantor Fitzgerald Starts Madrigal Pharmaceuticals With Neutral Rating MT
Transcript : Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM
More news

Quotes 5-day view

Date Price Change
24-07-16 0.43 +4.88%
24-07-15 0.41 -16.33%
24-07-12 0.49 -7.55%
24-07-11 0.53 -1.85%
24-07-10 0.54 -6.90%

Delayed Quote Börse Stuttgart

Last update July 16, 2024 at 11:32 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying MADRIGAL PHARMACEUTICALS, INC.
Issuer Morgan Stanley
WKN ME9H26
ISINDE000ME9H262
Date issued 2024-03-01
Strike 300 $
Maturity 2024-09-20 (66 Days)
Parity 50 : 1
Emission price 0.81 €
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.32 €
Lowest since issue 0.11 €
Delta0.48x
Omega 5.099
Premium16.29x
Gearing10.54x
Moneyness 0.9364
Difference Strike 23.33 $
Difference Strike %+7.78%
Spread 0.1 €
Spread %18.52%
Theoretical value 0.4800
Implied Volatility 71.23 %
Total Loss Probability 64.24 %
Intrinsic value 0.000000
Present value 0.4800
Break even 326.12 €
Theta-0.04x
Vega0.01x
Rho0x

Company Profile

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
More about the company

Consensus: Madrigal Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
280 USD
Average target price
365.3 USD
Spread / Average Target
+30.50%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant